GSK studies Chinese remedies to discover new drugs

Amid GlaxoSmithKline's ($GSK) major push to expand in China, the London-based drugmaker has located a new R&D unit in that country that will investigate traditional Chinese medicines. The move is part of an effort to discover new chemical entities for treating diseases, British newspaper The Telegraph reported Sunday. Last week GSK R&D honcho Moncef Slaoui shared the plans with FierceBiotech in an interview about the drugmaker's strategy for discovering and developing new products.  FierceBiotech's Slaoui interview | The Telegraph report

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.